Notice Period upon which Shares May be Repurchased Notice period Represents the notice period upon which shares may be repurchased. Pluristem License Agreement [Member] Pluristem License Agreement Represents information pertaining to the Pluristem License Agreement. Series A Junior Participating Preferred Stock [Member] Series A junior participating preferred stock. Series A junior participating preferred stock Convertible Notes Due 2016 Convertible Notes Due 2016 [Member] Represents convertible senior notes, which will mature in 2016. Discounted Cash Flow Valuation Technique [Member] Discounted Cash Flow Discounted cash flow valuation technique used to measure fair value. Technology, patents and trade names The exclusive legal right granted by the government to the owner of the patent and technology to exploit an invention or a process or a technology for a period of time specified by law and which also includes information related to rights acquired through the registration of a business name to gain or protect exclusive use thereof. Technology, Patents and Trade Names [Member] Privately-held corporations Represents information pertaining to the privately-held corporations. Privately Held Corporations [Member] Customer Relationships and Non Compete Agreements [Member] An asset acquired in a business combination representing a customer relationship that exists between an entity and its customer if (a) the entity has information about the customer and has regular contact with the customer, and (b) the customer has the ability to make direct contact with the entity. Such assets would include tenant relationships obtained through acquisition, unless otherwise included in acquired in-place leases. It also includes the payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time. Customer relationships and non-compete agreements Finite-Lived Contract Based Intangible Assets [Member] Represents the details pertaining to contract-based intangible assets which consisted of a license agreement. Contract-based Share Tracking Awards Plan [Member] Share tracking award plans (STAP) is a long-term, equity-based compensation plan for eligible participants. Awards granted under this plan are non-dilutive as they are not settled in shares of entity's common stock and convey the right to receive in cash an amount equal to the appreciation of entity's common stock. Share tracking award plans (STAP) Amendment Description Potential payments under the contingent consideration arrangement, including cash and shares as applicable. Contingent Consideration Contingent Consideration [Member] Amendment Flag Document and Entity Information Income before income tax Sum of operating profit and non-operating income (expense) including income (loss) from equity method investments, before income taxes, extraordinary items, cumulative effects of changes in accounting principles, and non-controlling interest. Income (Loss) before Income Taxes Provision for Doubtful Accounts and Inventory Write-down Provision for inventory obsolescence Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). This element also includes a charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions. License Costs Incurred but Not Paid Costs incurred, but not yet paid, that are directly related to obtaining license rights. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Expense associated with outstanding license fees Income Tax Cash Flows Current and deferred income tax expense Income tax expense (benefit) pertaining to the entity's operations. Payments of Convertible Debt Hedge and Warrants, Net Payment for convertible note hedge and warrants, net Represents the cash outflow with respect to payments for convertible note hedge and warrants, net. Represents the cash outflow with respect to the payment for accelerated share repurchase transaction cost. Payment for an accelerated share repurchase transaction Payment for an Accelerated Share Repurchase Transaction Cost Noncash change in the carrying amount of a long-term financing obligation structured as a synthetic lease arrangement. Increase (Decrease) Lease Financing Obligation Lease obligation incurred Basis of Presentation Stockholders' Equity Disclosures related to statement of shareholders' equity, including earnings per share and stock options disclosure. Comprehensive Income is included in a separate statement to the financial statements. Stockholders Equity Note Excluding Comprehensive Income Disclosure [Text Block] Litigation Fair Value Assets and Liabilities Measured on Recurring Basis Unobservable Input Reconciliation [Table Text Block] Schedule of reconciliations of the beginning and ending balances of Level 3 assets and liabilities Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets and liabilities) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets and liabilities) are reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability. Schedule of assumptions to estimate the fair value of STAP awards Tabular disclosure of the significant assumptions used during the year to estimate the fair value of share-based awards, including but not limited to: (a) expected term of the share-based awards, (b) expected volatility of the entity's shares, (c) expected dividends, and (d) risk-free rate(s). Schedule of Share-based Payments Award Other than Options Valuation Assumptions [Table Text block] Schedule of components of interest expense incurred in connection with the entity's convertible notes Tabular disclosure of interest expense related to convertible debt. Schedule of Interest Expense on Convertible Debt [Table Text Block] Schedule of Convertible Debt [Table Text Block] Schedule of information about carrying amount of the 2016 Convertible Notes Tabular disclosure of the carrying amount related to the convertible debt. Schedule of Interest Expense [Table Text Block] Schedule of components of interest expense presented on the entity's consolidated statements of operations Tabular disclosure of the components of interest expense during the period. Current Fiscal Year End Date Award Type [Axis] Tabular disclosure of employee and non-employee stock option exercise data. Schedule of Service Share-based Compensation, Employee and Nonemployee Stock Option Exercise Data [Table Text Block] Summary of employee and non-employee stock option exercise data Schedule of Revenue Cost of Revenue Gross Profit by Product [Table Text Block] Tabular disclosure of revenues, cost of revenues and gross profit for each of the entity's commercial product during the period. Schedule of revenues, cost of revenues and gross profit for each of the entity's commercial product Convertible Notes Due 2011 Convertible Notes Due 2011 [Member] Represents convertible senior notes, which matured in 2011. Business Acquisition, Contingent Consideration, Fair Value Disclosure Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement including cash and shares. Contingent consideration Represents interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value relating to contingent consideration. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. Cost of debt and weighted average cost of capital (as a percent) Fair Value Inputs Cost of Debt and Weighted Average Cost of Capital Discount Rate Tangible assets Business Acquisition Fair Value Allocation Tangible Assets Acquisition date fair value allocated based on the fair value of tangible assets acquired in a business combination. Fair value of net tangible assets acquired Business Acquisition Fair Value Allocation Net Tangible Assets Acquisition date fair value allocated based on the fair value of net tangible assets acquired in a business combination. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset (Liability) Gains (Losses) Realized (Unrealized) [Abstract] Total gains/(losses) realized/unrealized This element represents total unrealized gains or losses for the period included in earnings arising from liabilities still held at the reporting date that are measured at fair value on a recurring basis using unobservable inputs (Level 3). Amount of total gains/(losses) for the period included in earnings attributable to the change in unrealized gains or losses related to outstanding liabilities Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Liability Still Held Gain (Loss) Included in Earnings Held-to-maturity Securities, Debt Maturities in One Year Through Two Years, Net Carrying Amount This item represents debt securities, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are expected to mature after one year and through two years from the balance sheet date and which are categorized as held-to-maturity. Due in one to two years, Amortized Cost Held-to-maturity Securities, Debt Maturities in One Year Through Two Years, Fair Value This item represents the fair value of debt securities which are expected to mature after one year and through two years from the balance sheet date and which are categorized as held-to-maturity. Due in one to two years, Fair Value Document Period End Date The entity owns less than this percentage of common stock of an available-for-sale investee. Available-for-sale investment in common stock, less than a certain percentage Available-for-Sale Securities, Equity Securities Investment Percentage Less Than Goodwill and Other Intangibles Assets, Gross Sum of gross carrying amounts of all intangible assets including goodwill before accumulated amortization as of the balance sheet date. Total intangible assets, Gross Share Tracking Awards Plan 2011 [Member] The 2011 share tracking awards plan (STAP) is a long-term, equity-based compensation plan for eligible participants. Awards granted under this plan are non-dilutive as they are not settled in shares of entity's common stock and convey the right to receive in cash an amount equal to the appreciation of entity's common stock. 2011 share tracking awards plan (STAP) Increase in total number of awards available for grant (in shares) Represents the increase in total number of authorized awards available for grant under the award plan. Share-based Compensation Arrangement by Share-based Payment Award, Increase in Number of Authorized Shares Available for Grant Share-based Award Compensation Liability Represents the estimated fair value of share-based awards at the end of the reporting period that are accounted for as a liability due to cash settlement provisions. Equity based compensation liability Share-based Compensation Arrangement by Share-based Payment Award, Other than Options Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate (as a percent) The risk-free interest rate assumption that is used in valuing an award based upon its own shares. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Expected forfeiture rate (as a percent) The weighted average forfeiture rate assumption used by an entity in valuing an award based upon its own shares. The expected forfeiture rate may be derived from historical employee turnover rates and expectations about the future. Expected forfeiture rate (as a percent) The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the award's term. Share-based Compensation Arrangement by Share-based Payment Award, Other than Options Fair Value Assumptions Expected Dividend Rate Expected dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Outstanding [Roll Forward] A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Share-based awards activity Entity [Domain] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) The number of units under share-based plans other than stock option plans awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested awards. Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Outstanding Number Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercised in Period Exercised (in shares) Number of share-based units exercised during the current period. The number of units under share-based plans other than stock option plans awarded under the plan that validly exist and are outstanding and vested as of the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercisable Number Exercisable at the end of the period (in shares) Arrangements and Non-arrangement Transactions [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest Number The number of units awarded under share-based plans other than stock option plans that validly exist and are outstanding which are expected to vest as of the balance sheet date. Expected to vest at the end of the period (in shares) Share awards, Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award Other than Options Outstanding Weighted Average Exercise Price Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) The weighted average exercise price of outstanding awards at the balance sheet date. Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award Other than Options Grants in Period Weighted Average Exercise Price The weighted average exercise price as of the balance sheet date on units awarded under the plan during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercises in Period Weighted Average Exercise Price The weighted average price at which award holders exercised their awards under the plan during the reporting period. Exercised (in dollars per share) Forfeited (in dollars per share) The weighted average price at which grantees could have exercised with respect to awards that were terminated during the reporting period due to noncompliance with plan terms during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Forfeitures in Period Weighted Average Exercise Price The weighted-average price as of the balance sheet date on vested portions of awards outstanding and currently exercisable under the awards plan. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercisable Weighted Average Exercise Price Exercisable at the end of the period (in dollars per share) As of the balance sheet date, the weighted-average exercise price for outstanding awards that are expected to vest. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Expected to Vest Outstanding Weighted Average Exercise Price Expected to vest at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Other than Options Weighted Average Remaining Contractual Term Disclosures [Abstract] Share awards, Weighted Average Remaining Contractual Term The weighted average period between the balance sheet date and expiration for all vested portions of awards outstanding and currently exercisable (or convertible) under the plan, which may be expressed in a decimal value for number of years. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercisable Weighted Average Remaining Contractual Term Exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term The weighted-average period between the balance sheet date and expiration date for outstanding awards that are expected to vest, which may be expressed in a decimal value for number of years. Expected to vest at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Aggregate Intrinsic Value Disclosures [Abstract] Share awards, Aggregate Intrinsic Value The total dollar difference between fair values of the underlying shares indexed under the plan and exercise prices of vested portions of awards outstanding and currently exercisable under the award plan as of the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award Other than Options Exercisable Intrinsic Value Exercisable at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value As of the balance sheet date, the total dollar difference between fair values of the underlying shares indexed and exercise prices of outstanding awards that are expected to vest. Expected to vest at the end of the period (in dollars) Awards available for issuance (in shares) The number of awards available for issuance under the plan as of the balance sheet date. Share-based Compensation Arrangement by Share-based Payment Award, Number of Awards Available for Issuance Debt Instrument Conversion Obligation Trading Day Period Assessed Represents the number of days in consecutive trading-day period ending on the last trading day of the quarter that is used to determine if the contingent conversion requirement is met. Trading-day period used to determine contingent conversion requirement on notes The number of equity instruments upon which the aggregate consideration, both in cash and stock, is determined for conversion. Convertible debt, number of shares into which convertible Debt Instrument, Convertible, Number of Equity Instruments Aggregate Consideration Determined Percentage of conversion price that the closing sales price of the entity's common stock must exceed in order to make the notes convertible Represents the percentage of the closing sale price of the entity's common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the debt instruments to be convertible. Debt Instrument Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price Number of trading days within 30 consecutive trading days in which closing price of the entity's common stock must exceed conversion price for notes to be redeemable Represents the number of trading-days within a period of 30 consecutive trading days the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible. Debt Instrument Conversion Obligation Common Stock Closing Sales Price Number of Trading Days Number of consecutive business days immediately after any five consecutive trading-day period during note measurement period Number of consecutive trading days immediately after any five consecutive trading-day period during the note measurement period in which the notes can be converted. Debt Instrument Conversion Obligation Number of Consecutive Trading Days after Consecutive Trading Day Period Number of consecutive trading-days during which the trading price of the convertible notes must be less than a given percentage of the entity's stock price to be convertible. Number of consecutive trading days during which the trading price of the convertible notes is less than a specific percentage of the conversion price of the convertible notes. Debt Instrument Conversion Obligation Period of Consecutive Trading Days Debt Instrument Conversion Obligation Trading Price as Percentage of Product of Last Reported Common Stock Sale Price and Conversion Rate Maximum Percentage of trading price of the entity's common stock's closing price and the conversion rate, maximum Represents the maximum percentage of the trading price of each debt instrument to the product of the last reported sale price of the entity's common stock and the conversion rate of the debt instrument that the trading price must be less than in order for the debt instruments to be convertible. Amortization schedule Represents the amortization period for the debt instrument. Debt Instrument Amortization Period Carrying amount related to convertible notes Convertible Senior Notes [Abstract] Accumulated amortization of debt discount at the end of the reporting period. Debt Instrument, Accumulated Amortized Discount Discount, accumulated amortization Period Used in Computation of Annual Principal Payments Amortization schedule, period for calculation of monthly installments Represents the amortization period used in the calculation of monthly installments (principal and interest) that are due until the maturity date. Interest Rate Used in Computation of Annual Principal Payments Represents the fixed interest rate used in the calculation of annual principal payments of debt. Amortization schedule, fixed interest rate for calculation of principal payments (as a percent) Debt Instrument, Alternative Interest Rate Option Represents the alternative interest based on an option. Debt, interest rate, alternative option (as a percent) Debt Instrument, Alternative Interest Rate, Option Spread Over Federal Funds Effective Rate Represents the spread over the federal funds effective rate added to the alternative interest based on an option. Debt, interest rate, alternative option, spread over federal funds effective rate (as a percent) Debt Instrument, Alternative Interest Rate Option Basis Represents the basis for the rate added to the alternative interest based on an option. Debt, interest rate, alternative option, basis Debt Instrument, Alternative Interest Rate Option Spread Represents the spread over the basis for the rate added to the alternative interest based on an option. Debt, interest rate, alternative option, spread over basis (as a percent) Maximum consolidated leverage ratio Debt Instrument Financial Covenant Consolidated Leverage Ratio Represents the maximum consolidated leverage ratio allowed under the debt agreement. The leverage ratio is calculated as the ratio of the entities consolidated indebtedness to "Consolidated EBITDA" which is defined as consolidated net income, adjusted for the following as applicable: (i) interest expense; (ii) income taxes; (iii) non-cash license fees; (iv) depreciation and amortization; (v) impairment charges; and (vi) share-based compensation (stock option and share tracking awards expense), to be measured as of the last day of each fiscal quarter on a rolling four quarter basis. Debt Instrument, Financial Covenant Measurement Period Financial covenants, measurement period (in rolling quarters) Represents the measurement period, in rolling quarters, for financial covenants. Debt Instrument, Financial Covenants, Minimum Liquidity Amount Financial covenants, minimum liquidity amount Represents the minimum liquidity amount for financial covenants. Represents the portion of the liability related to vested STAP awards that is not included in the calculation of minimum liquidity under the Credit Agreement. Debt Instrument, Financial Covenants, Qualification Amount for Minimum Liquidity Financial covenants, portion of vested STAP awards not included in calculation Debt Instrument, Aggregate Conversion Value in Excess of Par Value Represents the amount by which the aggregate conversion value of the debt instrument as of the balance sheet date exceeds the par value. Amount by which aggregate conversion value exceeds par value Call Option Purchase [Abstract] Purchase of call options Sale of warrant Warrants [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term Disclosures [Abstract] Employee stock options, Weighted Average Remaining Contractual Term Share awards, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Disclosures [Abstract] Employee stock options, Aggregate Intrinsic Value Share Repurchase Stock Repurchase [Abstract] Entity Well-known Seasoned Issuer Noncurrent Federal Tax Expense (Benefit) Federal The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts paid or payable (or refundable) after one year as determined by applying the provisions of enacted federal tax law to the domestic taxable income or loss from continuing operations. Entity Voluntary Filers Noncurrent State and Local Tax Expense (Benefit) State The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts paid or payable (or refundable) after one year as determined by applying the provisions of enacted state and local tax law to relevant amounts of taxable income or loss from continuing operations. Entity Current Reporting Status Noncurrent Foreign Tax Expense (Benefit) Foreign The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts paid or payable (or refundable) after one year as determined by applying the provisions of foreign enacted tax law to the foreign taxable income or loss from continuing operations. Entity Filer Category Noncurrent Income Tax Expense (Benefit) Total other The component of other non-current income tax expense benefit primarily related to share-based compensation for the period representing amounts of income taxes paid or payable (or refundable) after one year for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable income or loss from continuing operations. Entity Public Float Commercial Products Number Number of commercial products The number of commercial products of the entity. Number of commercial products approved Entity Registrant Name Schedule of Revenue, Cost of Revenue Gross Profit by Product [Table] A table disclosing the revenue, cost of revenue and gross profit by commercial product. Entity Central Index Key Remodulin Remodulin [Member] Represents Remodulin, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH). Tyvaso [Member] Represents Tyvaso, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH). Tyvaso Represents Adcirca, a commercial product of the entity, for treating pulmonary hypertension. Adcirca Adcirca [Member] Revenue Cost of Revenue, Gross Profit by Product [Line Items] Revenues, cost of revenues and gross profit Entity Common Stock, Shares Outstanding Loss Contingency Period for which Lawsuit Would Preclude FDA from Approving ANDA Maximum period for which the FDA is automatically precluded from approving Sandoz's ANDA Represents the maximum period of time from receipt of a Notice Letter corresponding to a Abbreviated New Drug Application (ANDA) for which the FDA is precluded from approving the Abbreviated New Drug Application (ANDA), under the Hatch-Waxman Act. Shares received upon sale of subsidiary Shares Received upon Sale of Subsidiary Represents the shares received on the sale of the wholly-owned subsidiary of the entity. Stock Issued During Period, Value, Conversion of Convertible Securities and Shares Received Through Hedge Exercise The gross value of stock issued during the period upon the conversion of convertible securities and the gross value of shares received through the exercise of convertible note hedges. Conversion of 2011 convertible notes and exercise of convertible note hedge Adjustments to Additional Paid in Capital, Convertible Debt Hedge and Warrants, Net 2016 convertible note hedge and warrants, net of tax This element represents the adjustment made to additional paid-in capital due to difference between purchase of call option and sale of warrants. Distribution Agreements Distribution Agreements This element represents the disclosure relating to distribution agreements. Disclosures may encompass the contractual responsibilities between supplier and distributor, ordering specifications, inventory requirements and the amounts and timing of fees. Distribution Agreements Disclosure [Text Block] Concentrations of Credit Risk, Products, Revenues and Customers [Policy Text Block] Concentrations of Credit Risk, Products, Revenues and Customers Describes the entity's accounting policy relating to concentrations of credit risk, products, revenues and customers. Details pertaining to Accredo health group Inc., being a major customer of the entity. Accredo Health Group, Inc. Accredo Health Group, Inc. [Member] Number of Distributors Number of distributors Represents the number of distributors. Number of major customers Represents the number of major customers. Number of Major Customers Period for reclassification of operating results of Medicomp, Inc. Reclassification Period for Operating Result of Subsidiary Represents the reclassification period for operating results of subsidiary of the reporting entity. Buildings, Building Improvements and Leasehold Improvements [Member] Details pertaining to buildings, building improvements and leasehold improvements. Buildings, building improvements and leasehold improvements Furniture, Equipment and Vehicles [Member] Details pertaining to equipments used to produce goods and services. It also includes long-lived, depreciable assets, commonly used in offices and stores and for road transportation. Furniture, equipment and vehicles Revenue Recognition [Line Items] Revenue Recognition Shelf Life of Product, Minimum Shelf life of Remodulin and Tyvaso sold to customers, minimum Represents the minimum shelf life of a product. Holding Period of Inventory by Distributor, Low End of Range Inventory holding period of Remodulin and Tyvaso, low end of range Represents the low end of the range of the inventory holding period. Inventory holding period of Remodulin and Tyvaso, high end of range Represents the high end of the range of the inventory holding period. Holding Period of Inventory by Distributor, High End of Range Document Fiscal Year Focus Represents the maximum percentage of exchanges of Remodulin and Tyvaso as compared to the total volume of units sold. Percentage of Remodulin Exchanges to Total Volume of Vials Sold Maximum Maximum exchanges of Remodulin and Tyvaso as compared to the total volume of units sold (as a percent) Document Fiscal Period Focus Income Tax [Abstract] Income taxes Percentage of Likelihood of Realization of Recognized Tax Benefit, Minimum Minimum percentage of likelihood of realization of recognized tax benefit Represents the minimum percentage of likelihood of realization of recognized benefit. Accrued Royalties and Rebates, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties and rebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Royalties and rebates Accrued Research Related Costs, Current Research related Carrying value as of the balance sheet date of obligations incurred through that date and payable for research related costs, used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Tabular disclosure of future milestone payments required in the aggregate and for each of the five succeeding fiscal years and thereafter for assignment and license agreements upon the achievement of certain product development and commercialization goals as of the balance sheet date. Schedule of Future Milestone Rental Payments, under Assignment and License Agreements [Table Text Block] Future milestone payments under assignment and license agreements Future milestone payments under Assignment and License Agreements Future Milestone Payments Due [Abstract] 2013 For assignment and license agreements in excess of one year, milestone payments due within one year of the balance sheet date. Future Milestone Payments Due, Current For assignment and license agreements in excess of one year, milestone payments due within the second year of the balance sheet date. Future Milestone Payments, Due in Two Years 2014 For assignment and license agreements in excess of one year, milestone payments due within the third year of the balance sheet date. Future Milestone Payments, Due in Three Years 2015 For assignment and license agreements in excess of one year, milestone payments due within the fourth year of the balance sheet date. Future Milestone Payments, Due in Four Years 2016 Future Milestone Payments, Due in Five Years 2017 For assignment and license agreements in excess of one year, milestone payments due within the fifth year of the balance sheet date. Legal Entity [Axis] Thereafter For assignment and license agreements in excess of one year, milestone payments due after the fifth year of the balance sheet date. Future Milestone Payments, Due Thereafter Document Type The total of future contractually required payments on milestone payments under the assignment and license agreements. Future Milestone Payments, Due Total Accounting Policies [Abstract] Represents the details pertaining to research agreement with the University of Oxford (Oxford) to develop antiviral compounds. Research under this agreement is performed by Oxford Glycobiology Institute, which is headed by a member of our board of directors and our scientific advisory board. Oxford Glycobiology Institute Oxford Glycobiology Institute [Member] Royalty as a percentage of net sales Represents the royalty as a percentage of net sales. Royalty as Percentage of Net Sales Represents the estimated obligation in connection with the extension of the research agreement term. Research obligation in connection with extension of term Research and Development Obligation with Extension of Term Research expense, number of equal installments Represents the number of equal installments for payment of research expense. Number of Equal Installments for Payment of Research and Development Expense Share Based Compensation Arrangement by Share Based Payment Award Offering Period Offering period Represents the term of each offering period under the employee stock repurchase plan. Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Represents the outstanding payable related to the extension of the research agreement. Research and Development Expense, Extension Liability Amount Outstanding Amount payable under research agreement extension Other Development Expenses Other development expenses Represents the other development expenses. Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income, Net Actuarial Gain (Loss) before Tax Net unrecognized actuarial loss (gain) The aggregate net actuarial gains or losses recognized in other comprehensive income. Defined Benefit Plan, Accumulated Other Comprehensive Income Tax Amount Tax The tax portion of total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost. Defined Benefit Plan, Eligibility Age Eligibility age Represents participants' minimum retirement age in order to be eligible to receive benefit payments. Number of Months of Salary Taken as Gross Base for Receipt of Monthly Payments Number of months of salary taken as gross base for receipt of monthly payments Represents the number of months of salary taken as gross base for receipt of monthly payments. Vesting period of plan, when participants begin receiving payments Represents the vesting period of plan whereupon participants begin receiving payments from the plan. Defined Benefit Plan Vesting Period Total future estimated benefit payments Represents the total estimated amount of benefits expected to be paid. Defined Benefit Plan Expected Future Benefit Payments Additional number of new participants Represents the additional number of new participants. Defined Benefit Plan Additional New Participants Number Defined Contribution Plan, Employer Matching Contribution Percentage Employer's matching contribution, percentage Represents the percentage of employer's matching contribution. Defined Contribution Plan, Vesting of Matching Contribution, Service Period Period of service for vesting of matching contributions Represents the service period after which the matching contributions vest immediately. Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Defined Contribution Plan, Annual Increments Annual increments for vesting in employer's matching contribution Represents the annual increments for vesting in the employer's matching contribution over a three-year period. Defined Contribution Plan, Annual Increments Vesting Period Period over which the matching contribution vest annually Represents the period over which the matching contribution vest annually. Glaxo Smith Kline PLC [Member] Represents the information pertaining to license agreement with GlaxoSmithKline PLC (Glaxo), which has assigned patents and patent applications to the entity. GlaxoSmithKline PLC (Glaxo) Pfizer Inc. [Member] Represents the information pertaining to license agreement with Pfizer Inc. (Pfizer) exclusively licensed the entity to use patents and a patent application. Pfizer Inc. Supernus Pharmaceuticals, Inc. [Member] Represents the information pertaining to license agreement with Supernus Pharmaceuticals, Inc. (Supernus) for use of certain technologies developed by Supernus. Supernus Pharmaceuticals, Inc. Eli Lilly and Company [Member] Represents the information pertaining to license agreement with Eli Lilly and Company (Lilly), which has given the entity exclusive rights to develop, market, promote and commercialize Adcirca. Eli Lilly and Company Toray Industries, Inc. [Member] Represents the information pertaining to license agreement with Toray to obtain exclusive rights to develop and market beraprost, a chemically stable oral prostacyclin analogue. Toray Royalty Payment Term Minimum term of royalty payment Represents the minimum royalty payment term. Represents the installment payment term under the license agreement. Term of installment payments under license License Installment Payment Term Collaborative Arrangement, Common Stock Repurchase Price Per Share Price per share (in dollars per share) Represents the price per share the entity must pay on the repurchase of common stock issued to the counterparty of a collaborative agreement. The repurchase is at the discretion of the counterparty. Reduction in royalty percentage in the event of payment to third party Represents the reduction in royalty percentage in the event of payment to third party. Percentage of Reduction in Royalty Payment, Maximum Royalty Payment Obligation Amount Obligation and a corresponding charge to research and development expenses Represents the present value of the total obligation and corresponding charge to research and development expense. Royalty payments, remaining obligation Represents the remaining obligation amount of royalty payments. Royalty Payment, Remaining Obligation Amount Assignment and License Agreements Kurzweil Technologies, Inc. [Member] Details pertaining to Kurzweil Technologies, Inc. (KTI), a company controlled by Raymond Kurzweil. Kurzweil Technologies, Inc. Related Party Transaction, Royalty Rate Percentage of royalty agreed to be paid Represents the stated royalty rate as per the agreement. Related Party Transaction Royalty Rate, Maximum Percentage of royalty agreed to be paid, maximum Represents the maximum stated royalty rate as per the agreement. Accounts receivable, net of allowance of none for 2013 and 2012 Accounts Receivable, Net, Current Revivicor, Inc. [Member] Details pertaining to Revivicor, Inc., a company focused on developing genetic biotechnology platforms. Revivicor, Inc. Represents the milestone payments contingent upon receiving regulatory approvals. Milestone payments contingent upon receiving regulatory approvals Business Acquisition Contingent Milestone Payments on Receiving Regulatory Approvals Medicomp, Inc. [Member] Represents details pertaining to Medicomp, Inc., a wholly owned telemedicine subsidiary of the entity. Medicomp, Length of the term of the promissory note received in the sale of a business. Length of promissory note term Promissory Note Period Promissory Note, Interest Rate, Stated Percentage Promissory note, stated percentage Represents the stated interest rate of the promissory note. Percentage of Ownership Interest Held after Sale Percentage of ownership interest acquired after sale Represents the percentage of the entity's ownership interest acquired in the disposed business subsequent to its sale. Ownership Interest Acquired after Sale Cash Paid Ownership interest acquired after sale, cash paid Represents cash paid by the entity subsequent to the sale of the business to acquire an interest in the aforementioned business. Ownership Interest Acquired after Sale Reduction to Face Value of Promissory Note Ownership interest acquired after sale, reduction to face value of promissory note Represents the reduction in the face value of the promissory note from the disposed entity subsequent to the sale of the business to acquire an interest in the aforementioned business. Revenues and loss before income tax Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Equity Incentive Plan Equity Incentive Plan [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Contractual Term, Maximum Term of employee stock purchase plan Represents the maximum contractual term of options granted under the equity incentive plan which are nontransferable. Maximum contractual term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Period, Maximum Represents the maximum volatility period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Expected volatility maximum period Shareholders Rights Plan [Abstract] Shareholder Rights Plan Class of Warrant or Right Purchase Price of Right before Amendment and Restatement Purchase price of each Right, before the amendment and restatement of the Rights (in dollars per one one-thousandth of a share) Represents the purchase price of each right before the amendment and restatement of the rights. Represents the purchase price of each right after the amendment and restatement of the rights. Class of Warrant or Right Purchase Price of Right after Amendment and Restatement Purchase price of each Right, after the amendment and restatement of the Rights (in dollars per one one-thousandth of a share) Class of Warrant or Right Shares of Series A Junior Participating Preferred Stock Per Right Represents the number of shares of Series A Junior Participating Preferred Stock each right entitles a holder to purchase. Number of shares of Series A Junior Participating Preferred Stock each Right entitles a holder to purchase Class of Warrant or Right Condition on Exercise of Rights Minimum Percentage of Common Stock to be Acquired in Tender Offer Minimum ownership percentage in the outstanding shares of voting stock from the commencement of a tender offer that would result in the exercise of shares under one condition of the Agreement (as a percent) Represents the Minimum ownership percentage in the outstanding shares of voting stock from the commencement of a tender offer that would result in the exercise of shares under one condition of the agreement. The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to incentive stock option expense under enacted tax laws during the period. Income Tax Reconciliation, Incentive Stock Option Expense Incentive stock option expense License fees capitalized for tax purposes The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to license fees capitalized, which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Deferred Tax Assets, Capitalized License Fees The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to nonqualified stock options, which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Deferred Tax Assets, Nonqualified Stock Options Nonqualified stock options The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to supplemental executive retirement plan (SERP), which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Deferred Tax Assets, Supplemental Executive Retirement Plan SERP Represents the gross amount of net deferred tax assets before valuation allowance as of the balance sheet date, which results from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. Deferred Tax Assets, Net, before Valuation Allowance Net deferred tax asset before valuation allowance Pharmaceutical Represents information pertaining to the pharmaceutical segment. Pharmaceutical [Member] Recently Issued Accounting Standards Represents the recently issued accounting standards. New Accounting Pronouncements, Adopted, Disclosure [Text Block] Recently Issued Accounting Standards Accounts payable Accounts Payable, Current Assignment and License Agreements [Text Block] Describes the terms of license agreements including milestones, fees and royalties the company is, or may be required to pay under the agreements. Assignment and License Agreements Disclosure pertaining to the distribution agreements. Schedule of Distribution Agreements [Table] Greater than one year, Gross Unrealized Loss Held to maturity Securities Continuous Unrealized Loss Position 12 Months or Longer Accumulated Loss Amount of accumulated unrealized loss on investments in held-to-maturity securities that have been in a loss position for twelve months or longer. Gross Unrealized Losses Held to Maturity Securities Accumulated Unrecognized Holding Loss This item represents the excess of amortized cost basis over fair value of securities in a loss position and which are categorized as held-to-maturity. Gross Unrealized Loss, Total Details pertaining to distribution agreements with U.S.-based specialty pharmaceutical distributors. U.S. Based Specialty Pharmaceutical Distributors U.S. Based Specialty Pharmaceutical [Member] Less than one year, Gross Unrealized Loss Held to maturity Securities Continuous Unrealized Loss Position Less than 12 Months Accumulated Loss This item represents the excess of amortized cost basis over fair value of securities that have been in a loss position for less than 12 months for those securities which are categorized as held-to-maturity. International Distributors [Member] International Distributors Details pertaining to distribution agreements with the international distributors. Distribution Agreements [Line Items] Distribution Agreements Distribution agreement, initial term Represents the initial term for distribution agreement. Distribution Agreements, Initial Term Represents the additional terms for distribution agreement unless terminated earlier. Distribution Agreements, Additional Term Distribution agreement, additional terms Accounts receivable Accounts Receivable [Member] Proceeds from Distribution Agreements Payments received pursuant to distribution agreement Represents the amount received during the period pursuant to distribution agreements. Future milestone payments Represents the future milestone payments upon achievement of certain milestones. Distribution Agreements, Future Milestone Payments Increase (Decrease) in Insurance Proceeds Receivable Insurance proceeds receivable Represents increase decrease in insurance proceeds receivable during the reporting period. Note receivable Disposal Group Including Discontinued Operation Consideration Received Promissory Notes Balance Outstanding Represents outstanding balance of the note receivable, net of discount, as of the balance sheet date. Increase (Decrease) in Inventory Valuation Reserves Increase in reserves for obsolescence Represents the amount of increase (decrease) in the reserves for obsolescence. Remodulin and Tyvaso [Member] Remodulin and Tyvaso Represents information pertaining to Remodulin and Tyvaso, products of the reporting entity. Other Comprehensive Income (Loss) Amortization Gain (Loss) and Net Prior Service Costs Credit Arising During Period Net of Tax Less: amortization of actuarial gain and prior service cost included in net periodic pension cost, net of tax Net of tax amount of the income statement impact of the reclassification adjustment for the actuarial gain (loss) and prior service costs recognized as a component of net period benefit cost. Treasury Stock, Value, Acquired under Accelerated Repurchase Agreement Repurchase of shares Equity impact of the total cost, including the estimated fair value allocated to the forward contract component of common stock that was repurchased during the period. The treasury stock shares were recorded at cost. Cost of shares repurchased Maturity Principal Balance, Loans Payable to Bank Including the current and noncurrent portions, remaining principal value as of the maturity date of loan from a bank that will be due in full. Balance of debt remaining at maturity date Estimated Annual Effective Income Tax Rate Estimated Annual Effective Income Tax Rate Represents the estimated annual effective tax rate which is based on annual projections of pre-tax earnings and related taxes. Due in three to five years, Amortized Cost This item represents debt securities, at cost, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments, as defined), and fair value hedge accounting adjustments, if any, which are expected to mature after three year and through five years from the balance sheet date and which are categorized as held-to-maturity. Held to Maturity Securities Debt Maturities in Three Year Through Five Years, Net Carrying Amount Due after five years, Amortized Cost Carrying amount of debt securities accounted for as held-to-maturity, net of adjustments including, but not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized, and fair value hedge accounting adjustments, maturing after the fifth fiscal year following the latest fiscal year. Held to Maturity Securities Debt Maturities after Five Years, Net Carrying Amount Amortization of discount or premium on investments Accretion (Amortization) of Discounts and Premiums, Investments This item represents the fair value of debt securities which are expected to mature after three year and through five years from the balance sheet date and which are categorized as held-to-maturity. Held to Maturity Securities Debt Maturities in Three Year Through Five Years, Fair Value Due in three to five years, Fair Value Due after five years, Fair Value Amount of held-to-maturity debt securities at fair value maturing after the fifth fiscal year following the latest fiscal year. Held to Maturity Securities Debt Maturities after Five Years, Fair Value Accumulated Other Comprehensive Income (Loss) [Roll Forward] Changes in accumulated other comprehensive income (loss), net of tax A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Number of Indicating Events or Developments Number of indicating events or developments Represents the number of events or developments indicates that investment carrying amount may impaired. Number of eligible employees who may purchase more than 4000 shares Represents the number of eligible employees who may purchase more than 4000 shares during any offering period. Number of Eligible Employees who May Purchase More than Four Thousand Shares During Offering Period Borrowing capacity, accordion feature Borrowing capacity under the credit facility attributable to the accordion feature, which is at the discretion of the lending group. This capacity is additional to the maximum borrowing capacity under the credit facility (without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility). Line of Credit Facility Accordion Borrowing Capacity Temporary Equity Unamortized Discount On Convertible Debt Reclassified From Additional Paid In Capital To Temporary Equity Reclassification of Equity Component Represents the amount of unamortized discount reclassified from additional paid-in capital to temporary equity. Temporary Equity Convertible Note Due 2016 [Member] Temporary equity component in convertible note due 2016 Represents information relating to temporary equity component in convertible note which is due 2016. Temporary Equity Common Stocks Subject to Repurchase [Member] Temporary equity common stocks subject to repurchase Represents information relating to temporary equity common stocks subject to repurchase. Gross Unrealized Gains Held to Maturity Securities Accumulated Unrecognized Holding Gain Amount of accumulated unrecognized gain on investments in held-to-maturity securities. Rest-of-World European Union and Others [Member] Economic and political union of member states, located primarily in Europe and other countries outside of Europe but not United States. Three US Based Distributors [Member] Three U.S.-based distributors Represents information pertaining to three U.S.-based distributors. Concentration Risk Distributors Number Number of U.S.-based distributors Represents the number of U.S.-based distributors that account for majority of the entity's revenues. One Month LIBOR [Member] One-month LIBOR Represents information pertaining to the one-month LIBOR. Federal Funds Effective Rate [Member] Federal funds effective rate Represents information pertaining to the federal funds effective rate. Line of Credit Facility Additional Capacity Increase Option Additional increase in borrowing capacity of the line of credit available at the entity's option Represents the amount by which the borrowing capacity of line of credit may be increased at the entity's option, subject to certain conditions, under the terms of the credit agreement. Temporary Equity [Text Block] Temporary Equity Represents the entire disclosure for temporary equity includes securities: (1) with redemption features that are outside entities control; (2) that are not classified as an asset or liability; (3) that are excluded from permanent stockholders' equity; and (4) are not mandatorily redeemable. Amounts included in temporary equity relate to securities that are redeemable at a fixed or determinable price. UNITED STATES United States Accrued Expenses Accrued Liabilities, Current [Abstract] Accrued expenses Total Accrued Liabilities, Current Less-accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Defined Benefit Pension Plan Accumulated Defined Benefit Plans Adjustment [Member] Unrealized Gains and (Losses) on Available-for-Sale Securities Accumulated Net Unrealized Investment Gain (Loss) [Member] Balance at the end of the period Accumulated other comprehensive loss Balance at the beginning of the period Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income/(Loss) Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Table] Foreign Currency Translation Losses Accumulated Translation Adjustment [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Share-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Issuance of 2016 convertible notes Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Tax benefit from exercises of non-qualified stock options Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation expense, net of taxes Allocated Share-based Compensation Expense, Net of Tax Share-based compensation expense before taxes Allocated Share-based Compensation Expense Accounts receivable, allowance (in dollars) Allowance for Doubtful Accounts Receivable, Current Aggregate amortization expense relating to intangible assets Amortization of Intangible Assets Discount amortization Amortization of Debt Discount (Premium) Amortization of debt discount and debt issue costs Amortization of Financing Costs and Discounts Stock options and warrants excluded from calculation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Impairments Asset Impairment Charges Assets Assets, Fair Value Disclosure [Abstract] Total assets Assets Current assets: Assets, Current [Abstract] Assets Assets [Abstract] Total assets Assets of Disposal Group, Including Discontinued Operation Total current assets Assets, Current Total assets Assets, Fair Value Disclosure Assets Assets of Disposal Group, Including Discontinued Operation [Abstract] Auction-rate Securities Available-for-sale equity investment Available-for-sale Securities Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation Basis of Accounting [Text Block] Building improvements Building Improvements [Member] Buildings Building [Member] Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Business Acquisition [Axis] Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Contingent consideration at fair value Business Combination, Contingent Consideration, Liability Long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Acquisitions Business Acquisition [Line Items] Business Acquisition, Acquiree [Domain] Acquisitions Acquisitions Business Combination Disclosure [Text Block] Additional consideration upon the achievement of specific developmental and regulatory milestones Maximum contingent consideration upon achievement of milestones Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Acquisition date fair value of the assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Purchased call options Call Option [Member] Non-cash additions to property, plant and equipment Capital Expenditures Incurred but Not yet Paid Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Non-cash Investing activity: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Chief Executive Officer (CEO) Chief Executive Officer [Member] Share warrant, number of shares Number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Share warrant, exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Stock [Domain] Research agreement Assignment and License Agreements Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Commitments and Contingencies. Commitments and contingencies: Commitments and Contingencies Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common Stock Common Stock [Member] Common stock, par value $.01, 245,000,000 shares authorized, 62,802,440 and 62,082,007 shares issued, and 50,177,388 and 50,165,953 shares outstanding at September 30, 2013 and December 31, 2012, respectively Common Stock, Value, Issued Common stock, shares issued Common stock issued (in shares) Common Stock, Shares, Issued Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares outstanding Common Stock, Shares, Outstanding Supplemental Executive Retirement Plan Deferred tax assets: Components of Deferred Tax Assets [Abstract] Components of net deferred tax asset Components of Deferred Tax Assets and Liabilities [Abstract] Accumulated Other Comprehensive Income Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Concentration Risk Type [Domain] Concentrations of Credit Risk, Products, Revenues and Customers Segment Information Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk Type [Axis] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration risk, percentage Concentration Risk, Percentage Buildings under construction Construction in Progress [Member] Contingent Consideration Type [Domain] Contingent Consideration by Type [Axis] Convertible notes due 2016 Convertible Debt, Fair Value Disclosures Convertible Senior Notes Convertible senior notes Convertible Debt [Member] Convertible notes Convertible Notes Payable, Noncurrent Convertible notes Convertible Notes Payable, Current Corporate notes and bonds Corporate Debt Securities [Member] Cost of product sales Cost of revenues Cost of Goods Sold Investments in equity of privately-held corporations Cost Method Investments Cost of service sales Cost of Services Cost of goods sold Cost of product sales Cost of Sales [Member] Operating expenses: Costs and Expenses [Abstract] Total operating expenses Costs and Expenses Credit concentration Credit Concentration Risk [Member] State Current State and Local Tax Expense (Benefit) Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Foreign Current Foreign Tax Expense (Benefit) Federal Current Federal Tax Expense (Benefit) Total current Current Income Tax Expense (Benefit) Customer concentration Customer Concentration Risk [Member] Debt, floating rate of interest basis Debt Instrument, Description of Variable Rate Basis Debt Debt Instrument [Line Items] Schedule of Long-term Debt Instruments [Table] Debt aggregate principal value Debt Instrument, Face Amount Debt, floating rate of interest, basis spread (as a percent) Debt Instrument, Basis Spread on Variable Rate Debt Debt Security [Axis] Principal balance Long-term Debt, Gross Debt Debt Disclosure [Text Block] Debt, maturity term Debt Instrument, Term Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Redemption price of convertible notes as a percentage of principal amount, due to change in control Debt Instrument, Redemption Price, Percentage Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Convertible debt, discount to reduce net carrying value Debt Instrument, Unamortized Discount Convertible Senior Notes, stated percentage Debt, stated percentage Debt Instrument, Interest Rate, Stated Percentage Equity component Debt Instrument, Convertible, Carrying Amount of Equity Component Debt, interest rate at period end (as a percent) Debt Instrument, Interest Rate at Period End Federal Deferred Federal Income Tax Expense (Benefit) Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Foreign Deferred Foreign Income Tax Expense (Benefit) Total deferred Current and deferred income tax expense Deferred Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Net deferred tax assets Deferred Tax Assets, Net Deferred tax assets, net Deferred Tax Assets, Net, Noncurrent Deferred tax assets Deferred Tax Assets, Net, Current Total deferred tax assets Deferred Tax Assets, Gross STAP awards Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Other Deferred Tax Assets, Other Impairment losses on investments Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Business tax credit carryforwards General business credits Deferred Tax Assets, Tax Credit Carryforwards, General Business Valuation allowance Deferred Tax Assets, Valuation Allowance Other Deferred Tax Liabilities, Other Plant and equipment principally due to differences in depreciation Deferred Tax Liabilities, Property, Plant and Equipment Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Realized losses on marketable investments Deferred Tax Assets, Unrealized Losses on Trading Securities Amounts included in accumulated other comprehensive income expected to be recognized as components of net periodic pension cost Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year [Abstract] Total, net of tax Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), after Tax 2015 Defined Benefit Plan, Expected Future Benefit Payments, Year Three Projected benefit obligation at the end of the year Projected benefit obligation at the beginning of the year Defined Benefit Plan, Benefit Obligation Amortization of prior service cost Prior period service cost amortization Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Reconciliation of beginning and ending balances of the projected benefit obligation Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Actuarial loss (gain) Defined Benefit Plan, Actuarial Gain (Loss) 2014 Defined Benefit Plan, Expected Future Benefit Payments, Year Two Discount Rate (as a percent) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Amounts relating to the SERP that have been recognized in other comprehensive income Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Net unrecognized actuarial loss Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax 2017 Defined Benefit Plan, Expected Future Benefit Payments, Year Five Amortization of net actuarial loss Defined Benefit Plan, Amortization of Gains (Losses) Total Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax 2016 Defined Benefit Plan, Expected Future Benefit Payments, Year Four Total Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year Net unrecognized prior service cost Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax Amortization of prior service cost Defined Benefit Plan, Future Amortization of Prior Service Cost (Credit) Amortization of net actuarial loss Defined Benefit Plan, Future Amortization of Gain (Loss) 2013 Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months Supplemental Executive Retirement Plan Disclosure Defined Benefit Plan Disclosure [Line Items] Accumulated other comprehensive income (loss) that have not yet been recognized as a component of net periodic pension cost Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax [Abstract] Salary Increases (as a percent) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation 2018-2022 Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter Plan amendments Defined Benefit Plan, Plan Amendments Future estimated benefit payments Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract] Service cost Defined Benefit Plan, Service Cost Unfunded at end of the year Defined Benefit Plan, Funded Status of Plan Interest cost Defined Benefit Plan, Interest Cost Fair value of plan assets at the end of the year Defined Benefit Plan, Fair Value of Plan Assets Net pension expense Defined Benefit Plan, Net Periodic Benefit Cost Components of net periodic pension cost Defined Benefit Plan, Net Periodic Benefit Cost [Abstract] Expenses related to 401 (k) plan Defined Contribution Plan, Cost Recognized Weighted-average assumptions used to measure SERP obligation: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Defined Benefit Plan and Other Postretirement Benefit Plan [Domain] Employee Retirement Plan Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans [Axis] Net unrecognized prior service cost Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax Depreciation expense Depreciation Depreciation and amortization Depreciation, Depletion and Amortization Recently Issued Accounting Standards Description of New Accounting Pronouncements Not yet Adopted [Text Block] Share Tracking Award Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share Tracking Award Plans Income (loss) before income tax Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Sale of Medicomp, Inc. Income (loss) from discontinued operations, net of tax Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Gain on disposal of discontinued operations, net of tax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Other current liabilities Disposal Group, Including Discontinued Operation, Other Current Liabilities Cash Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Disposal Groups, Including Discontinued Operations, Name [Domain] Assets and liabilities at the end of the period Disposal Group, Including Discontinued Operation, Unclassified Balance Sheet Disclosures [Abstract] Deferred tax assets Disposal Group, Including Discontinued Operation, Deferred Tax Assets Sale of Medicomp, Inc. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Equipment and other assets Disposal Group, Including Discontinued Operation, Other Assets Revenues Disposal Group, Including Discontinued Operation, Revenue Payments due Due to Related Parties Basic Earnings Per Share, Basic [Abstract] Diluted Earnings Per Share, Diluted [Abstract] Earnings Per Common Share Earnings Per Share Reconciliation [Abstract] Earnings (Loss) per Share Earnings Per Share, Policy [Policy Text Block] Net income per basic common share (in dollars per share) Basic (in dollars per share) Earnings Per Share, Basic Net income per diluted common share (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted Net income per common share: Earnings per common share: Earnings Per Share [Abstract] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations Federal tax rate (as a percent) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Payroll related Employee-related Liabilities, Current Share-based compensation (benefit) expense recognized in connection with the STAP Share-based compensation expense related to outstanding awards Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Stock Options Employee Stock Option [Member] Employee Stock Purchase Plan (ESPP) Employee Stock [Member] Cash payments on awards exercised during the period Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards Related income tax (benefit) Related income tax benefit Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Share-based compensation capitalized as part of inventory Share-based compensation capitalized as part of inventory Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Tax benefits realized from options exercised Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options Cash received Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options Investment in Northern Therapeutics, Inc. Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity Component [Domain] Investment in Northern Therapeutics, Inc. Balance Estimate of Fair Value Measurement [Member] Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Measurement Frequency [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Recurring fair value measurements Fair Value, Measurements, Recurring [Member] Fair Value, Measurement Frequency [Domain] Assets and liabilities subject to fair value measurements Fair Value of Financial Instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair Value Measurements Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Fair Value Hierarchy [Domain] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Level 3